Dalfampridine Efficacy in Multiple Sclerosis Management

Dalfampridine, a sustained-release formulation of 4-aminopyridine, is the first approved oral therapy specifically indicated to enhance gait and mobility in people with multiple sclerosis (MS). By blocking voltage-gated potassium channels, it improves conduction in demyelinated nerve fibres, leading to measurable gains in walking speed, endurance and manual dexterity. Beyond ambulatory benefits, emerging evidence suggests positive effects on cognitive processing speed and fatigue, underscoring its potential role as a complementary symptomatic treatment. Clinical responders typically exhibit improvements in standard motor tests, while ongoing research seeks reliable predictors of individual benefit. Safety considerations revolve around transient adverse events such as urinary tract infections and dizziness, generally manageable under clinical supervision. As a globally adopted therapy, dalfampridine represents a key symptom-focused intervention, enhancing quality of life and daily function in a subset of patients living with MS.

Research from Nature Portfolio

Recent studies have elucidated an unconventional mechanism of action for 4-aminopyridine, the active moiety of dalfampridine. Investigations in neuronal and non-neuronal cell models revealed that 4-aminopyridine not only depolarises membranes to facilitate calcium influx but also sequesters calcium from intracellular stores, triggering exocytotic release of neurotransmitters independently of external calcium. This dual action may contribute to enhanced synaptic transmission in demyelinated pathways, offering a refined understanding of how dalfampridine restores neural conductance and potentially informing the development of next-generation symptomatic therapies.

Dalfampridine Efficacy in Multiple Sclerosis Management publication trend

The graph below shows the total number of articles in dalfampridine efficacy in multiple sclerosis management across all publications each year (not limited to Nature Index journals).

Technical terms

Dalfampridine: A prolonged-release potassium channel blocker that restores conduction in demyelinated central nervous system fibres.

Voltage-gated potassium (Kv) channels: Membrane proteins controlling repolarisation of neurones and regulating action potential propagation.

Timed 25-Foot Walk Test (T25FW): A standard measure of walking speed assessed by timing a patient over a fixed 25-foot course.

6-Minute Walk Test (6MWT): A submaximal exercise test measuring the distance a patient can walk in six minutes to evaluate endurance.

Cytokines: Small signalling proteins (e.g. interleukins, interferon-γ, tumour necrosis factor-α) that mediate immune and inflammatory responses.

Neurofilament light chain: A structural axonal protein released into blood and cerebrospinal fluid upon neuroaxonal damage, serving as a marker of neurodegeneration.

References

1. Dynamic walking features and improved walking performance in multiple sclerosis patients treated with fampridine (4-aminopyridine). BMC Neurology (2015).
2. Dalfampridine effects on cognition, fatigue, and dexterity. Brain and Behavior (2016).
3. 4-Аminopyridine sequesters intracellular Ca2+ which triggers exocytosis in excitable and non-excitable cells. Scientific Reports (2016).
4. Performance Measures and Plasma Biomarker Levels in Patients with Multiple Sclerosis after 14 Days of Fampridine Treatment: An Explorative Study. International Journal of Molecular Sciences (2024).
5. Post-marketing safety surveillance of dalfampridine for multiple sclerosis using FDA adverse event reporting system. Frontiers in Pharmacology (2023).
6. Dalfampridine in the treatment of multiple sclerosis: a meta-analysis of randomised controlled trials. Orphanet Journal of Rare Diseases (2021).